Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Mod... (the 24-week treatment period as compared...)

HOME >> MEDICINE >> TECHNOLOGY

Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain

Date:6/1/2009

the 24-week treatment period, as compared to ibuprofen, in patients at risk for NSAID-induced ulcers. The trials were conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA).

About HZT-501

HZT-501 is a novel, proprietary fixed-dose tablet combining the world's most prescribed NSAID, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill. It is anticipated that HZT-501 will provide effective pain relief and reduce stomach acidity during the peak time of ulceration risk, thus reducing the risk of NSAID-induced ulcers.

About the Arthritis and Pain Market

According to the Arthritis Foundation, arthritis affects 46 million people in the U.S. and costs the U.S. economy $128 billion annually. According to a study by the Centers for Disease Control and Prevention (CDC) for the National Arthritis Data Workgroup, due to the increasing aging population, arthritis is projected to increase by 40 percent in the next two decades. The CDC estimates that 67 million people will be affected by arthritis by 2030. Additionally, chronic pain affects an estimated 86 million American adults. NSAIDs are among the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced. Because the prostaglandins that protect the stomach are reduced, NSAIDs often cause ulcers in the stomach. NSAID-induced GI toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations annually in the U.S. alone.

If deaths from the gastrointestinal effects of NSAIDs were tabulated separately in the National Vital Statistics reports, these effects would equate to the 15th most common cause of death in the U.S. Studies h
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
2. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
5. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007

Post Your Comments:

(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...

(Date:6/19/2013)... -- Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...

(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...

[0] Drug Patent Watch [0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research

... , MINNEAPOLIS, Aug. 11 ProUroCare Medical, Inc. (OTC ... the required three centers in its FDA clinical study of the ... , ProUroCare began the current study with the ... having more than 40 patients enrolled overall. Since beginning, five ...

... Aug. 10 Bionovo, Inc. (Nasdaq: BNVI ) today announced second quarter ... , Company Highlights , , , ... in 27 patients with metastatic breast cancer showed ... evidence of clinical activity, in a heavily pretreated ...

Cached Medicine Technology:ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 2 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 2 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 5 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 6 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 7 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 8

ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology Bionovo Announces Second Quarter 2009 Highlights and Financial Results

(Date:6/19/2013)... This news release is available in Spanish . ... the field of neglected diseases, it goes by the name ... health research was devoted to conditions that accounted for 90 ... counteract this imbalance that the Drugs for Neglected Diseases initiative ... anniversary year, the organization has been granted the BBVA Foundation ...

(Date:6/19/2013)... 19, 2013 The Movement ... neurosurgeons, psychiatrists and urologists with specialists in physical ... works with patients and their family members to ... of life. Patients also have the opportunity to ... research. , “Movement disorders can be relentlessly progressive ...

(Date:6/19/2013)... (PRWEB) June 19, 2013 North ... announced organizational changes to advance development of its ... said, “To support the advanced development of our ... changes to the Company’s management structure and engaged ... The Company announced that Michael Galiger will serve ...

(Date:6/19/2013)... Monroe, OH (PRWEB) June 19, 2013 DiscountFurnaceFilter.com, ... is excited to offer the 5-2-1 Compressor Saver kit at ... a Hard Start Kit) aids the air conditioning unit during ... helping to prevent air compressor or unit burn out. , ... start up so the air conditioner uses less power to ...

(Date:6/19/2013)... Kansas City will host its first Ciclovia event on ... A section of Main Street in the midtown area will be ... event. The Main Street Corridor Development and BikeWalkKC ... City join the ranks of dozens of cities across the US ... community vibrancy and active lifestyles. , “Ciclovia is the perfect event ...

Breaking Medicine News(10 mins):Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2 Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3 Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4 Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5 Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2 Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2 Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3

[0] DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation [0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center [0] Entegrion Announces Organizational Changes to Support Advanced Product Development [0] DiscountFurnaceFilter.Com is Pleased to Offer the 5-2-1 Compressor Saver Kit at an Exceptional Price [0] Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia

... 2009 U.S. Sales Up 191% - , , - Total Net ... Conference Call to be Held Today at 3:30 pm Central Time - ... (Amex: UPI ), a medical device company that develops, manufactures ... results for the fourth quarter and full year ended March 31, 2009. ...

... Mass., June 4 PLC Systems Inc. (OTC Bulletin Board: ... device-based technologies, today announced the appointment of Louis Brenner, M.D. ... Senior Vice President at AMAG Pharmaceuticals, Inc., fills the seat ... , , Dr. Brenner, 39, brings to the PLC ...

... volunteers who led more than one million people in March for Babies ... of Dimes raise urgently needed funds for programs that help moms and ... a premature child, I know firsthand the toll that premature birth can ... supporting the March of Dimes," says Sherri Shepherd , ...

... research that has suggested excess weight worsens disease , THURSDAY, ... may not worsen asthma, as many experts have thought, but ... manage the chronic condition. , Inhaled corticosteroids are the most ... with asthma, many of whom are overweight or obese. , ...

... (NYSE: CBM ) announced today that it has ... the Company that it is in compliance with the revised ... on April 14, 2009, the Company had failed to meet ... over a consecutive 30-day period and total shareholders, equity had ...

... night, the America,s Health Insurance Plans (AHIP) Foundation paid ... Group Health Cooperative of South Central Wisconsin, and L.A. ... designed to improve the health and environment of communities ... health plans of working with local partners in a ...

Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results PLC Systems Announces Appointment of Louis Brenner, M.D. to Board of Directors Celebrities Lead One Million Walkers and Urge Public to Support March for Babies(R)Obesity May Dampen Response to Asthma Meds Cambrex Regains Compliance With Revised NYSE Listing Standards AHIP Foundation Announces 2009 Community Leadership Awards

Made exclusively from LactoSorb® Resorbable Copolymer....

The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...

... Stryker Conquest Suture Retrievers ... that pierce through soft ... through the tissue to ... Conquest Retrievers are front ...

... excising soft tissue more efficiently than a punch ... edge on the straight scissor helps to maintain ... jaws for more efficient resection.,The curved scissors, available ... perfect tools for ACL stump removal, meniscectomies and ...

Medicine Products:

Meniscal Staple Bioabsorbable (PLLA) Wedge Interference Screws Conquest Suture Retrievers Scissor, Serrated Tooth Straight Tip, 3.4 mm Straight Shaft (b)